Evaluation Addressing Menopausal Symptoms in Primary Care with Newer Treatment Options Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Describe the burden, impact, and suboptimal management of menopause and its associated symptoms 5 4 3 2 1 Assess the mechanisms, safety, and efficacy of FDA-approved and non FDA-approved hormonal and non-hormonal therapeutic interventions for menopausal symptoms 5 4 3 2 1 Implement newer FDA-approved options into routine care for the optimal treatment of patients experiencing menopausal symptoms 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Jeffrey Levine, MD, MPH 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients with menopausal symptoms do you see during a typical month? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No Which of the following statements regarding the impact of menopause is TRUE? Depression is more prevalent among premenopausal women than perimenopausal women On average, postmenopausal females have lower fasting blood glucose levels than premenopausal women Up to 84% of postmenopausal women are affected by urogenital syndrome of menopause (UGM) Vasomotor symptoms (VMS) do not demonstrate racial and ethnic variations Larissa, your 57-year-old female patient, is experiencing severe vasomotor symptoms (VMS). Menses stopped 15 months ago, and she has an intact uterus. She has no depressive symptoms, and no history of breast cancer, CAD, VTE, liver or kidney disease. She is taking allopurinol, a CYP1A2 inhibitor, to prevent recurrence of gout. Which of the following options would you prescribe, based on the NAMS guidelines? An insertable 10-μg estradiol vaginal tablet Bioidentical 17β-estradiol combined with progesterone Neurokinin receptor inhibitor Ospemifene Which of the following approved agents blocks the neurokinin-3 receptors that play a role in regulating temperature? 17β-estradiol Bazedoxifene Fezolinetant Paroxetine Severe VMS are associated with increased risks for which of the following? Aneurysm and dyslipidemia Depression and diabetes Obesity and sleep apnea Osteoarthritis and sarcopenia Please rate your ability to implement newer FDA-approved options in to routine care for the management of symptoms related to menopause. Excellent Very good Good Fair Poor Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often (select all that apply): Utilize newer hormonal and non-hormonal therapies that have been found to reduce VMS and VVA while decreasing the cardiovascular risk of systemic hormonal exposure Make informed recommendations for therapies based on individual patient profile and the latest available clinical evidence regarding menopause Evaluate efficacy and safety data associated with hormone therapy options for treating menopause Implement NAMS guidelines regarding hormonal and non-hormonal options for addressing VMS and VVA Develop patient-centered management plans that underscore the importance of shared decision-making and patient activation as major components of successful menopause treatment Other, please specify: Previous